The objective of Translational Tools for Biomedical Innovation in Atherothrombosis — TransinAthero — is to fight human atherothrombotic pathologies in a public-private network while improving the biological, scientific and medical career perspectives of Early-Stage Researchers (ESR) and Experienced Researchers (ER) in the field of the most commonly occurring cardiovascular disease.
This Network will foster translaboratory and transUniversity training in the specific area of human translational research in atherothrombotic disease. TransinAthero partners have chosen to share their expertise and research to define the guidelines of atherothrombosis research for optimal efficacy in 5 workpackages and 10 training sessions focusing on different questions and technologies.
The TransinAthero network cumulates several unique strengths:
The TransinAthero network is thematically focused on human atherothrombosis. Participants have a unified vision of human atherothrombotic diseases and deploy their research efforts along a translational research axis going from the establishment of human tissue biobanks towards the design of the future diagnostic, and therapeutic tools. Along this axis, the participants develop methodological approaches based on the most up-to-date biological tools.
Our translational aims are supported by strong partnerships with private companies that are full partners in the present proposal.
ESR/ER will receive high-quality and comprehensive training. TransinAthero will proffer more than 60 ECTS. Cumulatively, 190-240 ESR/ER will follow our training sessions, during a cumulated teaching time of 91-98 days.
One additional ancillary aim of our network is to share and diffuse among participants the best practice and to disseminate the use of new tools emerging in our field of research.
Our network is based on a pre-existing network of public and private multidisciplinary organizations that are worldwide leaders in the field of atherothrombosis. Indeed, several participants are partners of an FP7 large-scale integrated program: “Fighting Aneurysmal Disease” and of the Leducq Foundation TransAtlantic Network of Excellence in Atherothrombosis.
